1. Home
  2. SPRO vs CRT Comparison

SPRO vs CRT Comparison

Compare SPRO & CRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPRO

Spero Therapeutics Inc.

N/A

Current Price

$1.14

Market Cap

71.0M

Sector

Health Care

ML Signal

N/A

Logo Cross Timbers Royalty Trust

CRT

Cross Timbers Royalty Trust

N/A

Current Price

$13.07

Market Cap

63.9M

Sector

Energy

ML Signal

N/A

Company Overview

Basic Information
Metric
SPRO
CRT
Founded
2013
1991
Country
United States
United States
Employees
N/A
2
Industry
Biotechnology: Pharmaceutical Preparations
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
71.0M
63.9M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SPRO
CRT
Price
$1.14
$13.07
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
355.5K
24.8K
Earning Date
05-13-2026
04-14-2026
Dividend Yield
N/A
5.29%
EPS Growth
111.81
N/A
EPS
N/A
N/A
Revenue
$66,802,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$300.00
N/A
P/E Ratio
N/A
$11.55
Revenue Growth
39.24
N/A
52 Week Low
$1.08
$7.07
52 Week High
$3.08
$11.90

Technical Indicators

Market Signals
Indicator
SPRO
CRT
Relative Strength Index (RSI) 32.01 88.94
Support Level $1.13 $10.18
Resistance Level $1.29 N/A
Average True Range (ATR) 0.04 0.35
MACD 0.01 0.19
Stochastic Oscillator 15.53 97.19

Price Performance

Historical Comparison
SPRO
CRT

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About CRT Cross Timbers Royalty Trust

Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.

Share on Social Networks: